Peptides in Competitive Sport

Four Rulebooks on the Athlete’s Desk

The easiest way to understand peptides in competitive sport is to imagine that every athlete has four separate rulebooks sitting on the same desk.

The mistake many people make is assuming that if a substance is acceptable under one rulebook, it must also be acceptable under the others.

It does not work that way.

A peptide, medication, supplement, hormone, or research compound can be acceptable in one context and restricted in another. The same substance can therefore receive different answers depending on which question is being asked.

The four rulebooks are:

1. Canadian law and regulatory status
2. Medical use and clinical care
3. Anti-doping rules
4. The rules of the athlete’s specific federation or competition

Understanding the difference between those four systems makes the rest of the subject much easier to follow.

Rulebook One: Is the Substance Legal?

The first question is a legal and regulatory one.

Can the substance legally be prescribed, sold, possessed, imported, compounded, supplied, or used in the context being discussed?

That answer depends on the substance, how it is being supplied, the jurisdiction, and the intended use.

Some compounds are approved medications with recognized clinical uses. Others may be investigational. Some may be available for laboratory research but not approved for human therapeutic use. Still others may fall under additional regulatory restrictions.

Those distinctions matter, but they answer a legal or regulatory question.

They do not automatically answer whether the substance is permitted in sport.

An athlete could therefore have a product that is legally prescribed and still face a separate anti-doping restriction.

Likewise, the fact that something can be purchased does not mean that a sporting organization must allow its use.

Sporting eligibility is a separate layer.

Rulebook Two: Is the Substance Medically Appropriate?

The second rulebook belongs to medicine.

A physician may decide that a particular medication is appropriate for a patient’s condition. A specialist may recommend a treatment because the expected medical benefit outweighs the potential risk.

That decision is based on healthcare.

The physician is considering questions such as:

What condition is being treated?

Is there a recognized medical indication?

What evidence supports the treatment?

What risks need to be monitored?

What alternatives exist?

Those are important questions, but they are still not the same questions that an anti-doping organization is asking.

A doctor can legitimately prescribe a medication that appears on a prohibited list.

This is why the existence of a prescription does not automatically create permission to compete while using the substance.

Instead, the athlete may have to determine whether a Therapeutic Use Exemption or another medical-exemption process applies.

The important lesson is that medical approval and sporting permission can both be valid decisions while reaching different conclusions.

The doctor may say:

“This treatment is appropriate for you.”

The sport may separately say:

“This substance is normally prohibited under our rules.”

The exemption process exists to resolve that conflict when the applicable requirements are met.

Rulebook Three: What Do the Anti-Doping Rules Say?

The third rulebook is the anti-doping framework.

This is where WADA, national anti-doping organizations, prohibited substance categories, testing standards, therapeutic exemptions, sample collection procedures, and anti-doping rule violations enter the picture.

This rulebook is not primarily concerned with whether a product can legally be purchased or whether a physician believes it is medically useful.

Its concern is whether the substance or method is permitted under the rules governing fair competition.

That can produce results that initially surprise people.

A substance may be medically useful but prohibited in sport.

A substance may be unapproved for therapeutic use and also prohibited.

A substance may not be individually named but still fall within a prohibited category.

A substance may be permitted outside competition but restricted during competition.

Another may be prohibited at all times.

The athlete therefore needs to understand more than a list of names.

They need to understand how the anti-doping framework classifies substances.

This becomes especially important with peptides because many anti-doping categories are built around biological families and mechanisms rather than around simple product names.

A person searching only for the word printed on a vial may miss the larger category that captures the substance.

Rulebook Four: What Does My Federation Actually Require?

The fourth rulebook belongs to the organization conducting the competition.

This is where the situation becomes even more important for athletes outside traditional Olympic sport.

A federation may follow WADA rules directly.

It may adopt them with modifications.

It may maintain its own prohibited list.

It may impose longer exclusion periods for certain substances.

It may use its own eligibility declarations.

It may use urine testing.

It may use blood testing.

It may combine testing with polygraph screening.

It may define “natural” competition in a way that is stricter than another federation.

This means that knowing the WADA status of a substance may not always be the end of the analysis.

An athlete also needs to ask:

What organization am I actually competing under?

That question sounds obvious, but it is surprisingly easy to overlook.

An athlete may compete in one federation for several years and then enter an event operated by another organization.

The sport may look the same.

The rules may not be.

The Same Athlete Can Receive Four Different Answers

Consider a hypothetical athlete recovering from an injury.

A clinic discusses a peptide-related treatment.

Under the first rulebook, the athlete asks whether the substance is legally available in the relevant context.

Under the second, the athlete asks whether the treatment is medically appropriate.

Under the third, the athlete asks whether anti-doping rules prohibit the substance.

Under the fourth, the athlete asks whether their particular federation imposes any additional eligibility requirement.

Those are four separate questions.

It is entirely possible for the first two answers to appear favourable while the third or fourth creates a problem.

This is why statements such as:

“My doctor said it was okay”

or

“I bought it legally”

do not settle the sporting question.

They may be accurate statements.

They simply answer different questions.

Passing One Rulebook Does Not Mean You Pass All Four

This is the central analogy of the article.

Think of the athlete moving through four checkpoints before competition.

At the first checkpoint, the question is legality.

At the second, medical appropriateness.

At the third, anti-doping status.

At the fourth, federation eligibility.

Passing through one gate does not open all of the others.

A prescription does not automatically open the anti-doping gate.

A research label does not open the competition gate.

A product being absent from a pharmacy does not tell us whether WADA prohibits it.

A product being absent from an exact-name search does not necessarily mean it falls outside a prohibited class.

Each gate has to be considered on its own.

Why This Analogy Matters for Peptides

Peptides are particularly suited to this four-rulebook model because they exist across several very different worlds.

Some peptides are naturally produced in the human body.

Some are approved medicines.

Some are pharmaceutical analogues.

Some remain investigational.

Some are sold for research purposes.

Some are discussed heavily in bodybuilding or recovery communities.

Some influence pathways that anti-doping organizations specifically regulate.

That mixture creates confusion.

A reader may encounter a substance in a scientific paper and assume that makes it medically available.

They may see it prescribed somewhere and assume it is allowed in competition.

They may see it sold online and assume it is legal for personal use.

They may not find its exact name in a search and assume it is not prohibited.

The four-rulebook model forces us to separate those assumptions.

One More Rule: Time Matters

There is another complication that sits across all four rulebooks.

The answers can change.

Regulatory approvals change.

Medical evidence develops.

Anti-doping lists are revised.

Federation policies are updated.

Testing methods improve.

A substance that was not discussed prominently several years ago may receive much greater attention today.

This is why athletes should not treat a previous answer as permanent.

The four rulebooks need to be checked against the current season and current rules.

That point becomes especially important later when we discuss stored samples and reanalysis.

Anti-doping science can advance after the athlete has already competed.

The rules are not completely static, and neither is the technology used to enforce them.

The Athlete Is Standing at the Intersection

This analogy also helps explain why responsibility feels complicated.

No single professional necessarily sees the entire picture.

A physician may understand the medical rulebook extremely well.

A pharmacist may understand medications and interactions.

A coach may understand training and federation culture.

A lawyer may understand regulatory law.

A federation official may understand competition eligibility.

An anti-doping organization may understand prohibited substance rules and testing.

The athlete is often the only person standing at the intersection of all of them.

That does not mean the athlete is expected to become a physician, lawyer, chemist, and anti-doping specialist.

It means the athlete needs to recognize when a question belongs to a different rulebook.

That skill alone prevents many bad assumptions.

If a doctor answers a medical question, the athlete should still ask the sport question.

If a retailer answers a product question, the athlete should still ask the regulatory question.

If another competitor answers from experience, the athlete should still verify the current federation rules.

A Better Way to Think Before Competition

Instead of asking one broad question such as:

“Can I use this peptide?”

the athlete can break the problem into four smaller questions:

Is this substance legally available for the intended purpose?

Is there a legitimate medical reason for its use?

What does the applicable anti-doping framework say about it?

What does my actual federation or competition require?

Those questions produce a much more reliable answer.

They also explain why two people can appear to disagree about the same substance while both are answering different parts of the problem.

One person may be discussing legality.

Another may be discussing medicine.

Another may be discussing WADA.

Another may be discussing a natural bodybuilding federation.

Unless everyone identifies the rulebook they are using, the conversation quickly becomes confusing.

Understanding the rules is one thing. Understanding how the anti-doping system actually operates is another.

Most athletes will never see the entire system at once. They may encounter only one part of it: checking a medication, receiving a testing notification after an event, providing a urine sample, or hearing that another athlete has been suspended. Behind those individual moments is a much larger process that includes rule-setting, risk assessment, athlete selection, sample collection, laboratory analysis, biological monitoring, intelligence gathering, results management, and, in some circumstances, disciplinary proceedings.

For Canadian athletes competing within the Canadian Anti-Doping Program, Sport Integrity Canada serves as the national anti-doping organization. The current Canadian Anti-Doping Program is aligned with the World Anti-Doping Code and is used by participating national and multi-sport organizations. A new 2027 program has been released for adoption, but it does not come into force until January 1, 2027. For an athlete, however, the practical starting point remains much simpler: determine which anti-doping framework governs the competition and what responsibilities come with participating under it.

Who is actually subject to anti-doping rules?

Not everyone who plays a sport or exercises in a gym is automatically subject to the same anti-doping system.

A recreational runner who enters a local charity race may have very different obligations from a national-team athlete. A university competitor may operate under a formal Canadian anti-doping framework. An Olympic-pathway athlete may be subject to both national and international federation requirements. A natural bodybuilder may compete under a private federation with its own prohibited list and testing procedures.

This is why the phrase “WADA athlete” can be misleading when used casually. WADA establishes the global Code and international standards, but athletes are generally brought under those rules through the organizations and competitions in which they participate.

In Canada, national sport organizations and other participating organizations can adopt the Canadian Anti-Doping Program as a condition of participation. Athletes and support personnel within those organizations then accept corresponding responsibilities. Sport Integrity Canada currently identifies several athlete categories, including athletes in international or national registered testing pools, national athlete pools, international-level athletes, and domestic or student-athletes. The responsibilities attached to those groups can differ, particularly in areas such as whereabouts reporting and medical exemptions.

For the average competitor, the important lesson is that anti-doping responsibility is connected to participation, not simply fame or professional status.

An athlete should therefore know who governs the event before trying to determine whether a particular peptide, medication, or supplement is permitted.

The first question is whether a substance is prohibited at all times or only in competition

Once an athlete knows which rules apply, timing becomes important.

The WADA Prohibited List separates substances and methods that are prohibited at all times from those restricted only during the in-competition period. “At all times” means both in competition and out of competition.

That distinction matters greatly when peptides are involved because several of the categories most relevant to peptide hormones, growth factors, related compounds, and non-approved substances fall within the prohibited-at-all-times framework.

An athlete can therefore make a serious mistake by thinking only about competition day.

Suppose an athlete’s competition is in August and the athlete uses a prohibited-at-all-times compound during rehabilitation in February. Asking whether the compound will still be detectable in August misses the more fundamental question. If the rules prohibited its use in February, the issue is not limited to whether it remains measurable months later.

This is why anti-doping education should focus on permission rather than detection windows.

The useful question is:

Was this substance permitted when I used it?

Not:

Will the test still find it when I compete?

How an athlete should check a substance

The checking process should begin with the exact active substance, not a nickname, product category, or marketing description.

A label saying “recovery peptide” is not enough. Neither is a clinic’s product name. Athletes need to identify what the substance actually contains because anti-doping rules apply to active compounds and biological classes rather than marketing language.

The next step is to check the current Prohibited List and, where applicable, a recognized medication database such as Global DRO. Canadian athletes can use Global DRO to check the status of many medications against applicable anti-doping rules.

This system is extremely useful, but it has limits. It is primarily a medication-status resource. The absence of a research peptide, supplement, or experimental compound from a search result does not automatically establish that the substance is permitted.

The athlete should then check the rules of the actual federation or competition. This becomes particularly important when competing outside mainstream WADA-aligned sport. A natural bodybuilding or powerlifting organization may have its own banned-substance policy, eligibility period, testing system, or declaration requirement.

Where a medication is medically necessary but prohibited, the athlete may also have to determine whether a Therapeutic Use Exemption is required and whether the exemption must be obtained before competition or can be considered under another applicable process.

A sensible athlete also keeps a record of this checking process. Saving the date, search result, medication name, federation rule, and relevant correspondence can be useful if questions arise later.

The goal is not to build a legal defence after the fact. It is to avoid uncertainty before the substance is used.

Anti-doping testing starts before a sample is ever collected

A common image of drug testing is that officials appear after a competition and randomly choose athletes to provide samples.

Random testing does occur, but modern anti-doping programs are more strategic than that.

Sport Integrity Canada describes its testing program as both unpredictable and intentional. Athletes may be selected based on finishing position, random selection, sport-specific risk, targeted testing, or intelligence received by the organization.

This means testing is not necessarily distributed equally across every athlete, sport, or moment in a season.

Some sports present different doping risks from others. Particular physiological demands may make certain prohibited substances more relevant in endurance sport, strength sport, or other disciplines. Competition schedules, training periods, prior testing information, biological-passport data, and credible intelligence can all help shape a testing program.

The important point is that modern anti-doping does not rely exclusively on luck.

An athlete can be selected randomly, but an athlete can also be selected because there is a specific reason for testing.

In-competition testing and out-of-competition testing

Testing can occur during competition, but it can also happen at training locations, training camps, an athlete’s residence, or other locations throughout the year.

Out-of-competition testing is particularly important for substances prohibited at all times. Without it, an athlete could theoretically use certain prohibited substances during training and simply hope to avoid testing until competition.

No-notice testing reduces that opportunity.

The athlete generally does not receive advance warning that a doping control officer is coming. Once the athlete is formally notified, specific responsibilities begin. The athlete is informed of the sample type being requested and of their rights and responsibilities during the collection process.

Depending on the circumstances, that request may involve urine, venous blood, dried blood spot testing, or a combination of sample types.

This is the point at which the anti-doping system moves from regulation into physical evidence collection.

What happens when an athlete is notified for testing?

Notification is a formal step.

An authorized chaperone or doping control officer identifies the athlete and explains that they have been selected for doping control. The athlete is told what type of sample is required and is informed of their rights and responsibilities.

In Canada, athletes have the right to ask questions, request a representative, obtain an interpreter when available, document concerns, and request certain modifications or reasonable delays where valid circumstances exist.

At the same time, the athlete has responsibilities. These include complying with the process, remaining within sight of sample-collection personnel after notification where required, providing identification, reporting to the doping-control station, and maintaining control of their sample until it has been secured.

That combination of rights and responsibilities is important.

Doping control is not supposed to be an informal interaction in which someone simply takes a specimen and leaves. It is a documented process designed to protect both the integrity of the sample and the rights of the athlete.

Urine testing: more than simply “peeing in a cup”

Urine remains one of the most familiar anti-doping sample types because many prohibited substances, metabolites, and markers can be detected in urine.

The process is highly controlled because the integrity of the sample matters as much as the analytical technology used later.

The athlete selects collection equipment, provides the sample under observation, and retains control of the collection vessel until the sample is transferred and sealed. Observation is required because the testing authority has to know that the urine being submitted actually came from the athlete being tested.

The urine is then divided between containers identified as the A and B samples. The athlete and doping control officer confirm that the identifying codes match the paperwork and collection kit before the samples are securely sealed.

The athlete’s name is not simply written across the laboratory sample as though it were an ordinary doctor’s-office specimen. Coding helps separate the analytical process from the athlete’s personal identity.

The sample’s specific gravity is also checked. In practical terms, this is a measurement of urine concentration. If the sample is too dilute to satisfy the applicable testing requirements, the athlete may be required to provide an additional sample.

This does not mean that diluted urine automatically proves wrongdoing. Hydration can affect urine concentration. The purpose of the check is to make sure the laboratory receives a specimen suitable for reliable analysis.

The athlete is also asked to declare medications, supplements, and other relevant substances used within the applicable reporting period. That information becomes part of the doping-control documentation and may assist later interpretation.

Why there are A and B samples

The A and B system is an important safeguard that many general readers have heard about but may not fully understand.

The A sample is generally the portion analyzed first.

The B sample is securely retained and can play a role when an adverse analytical finding requires further confirmation under the applicable results-management process.

The existence of a B sample provides an additional layer of procedural protection. It allows the analytical finding to be examined through a second sealed portion originating from the same original collection.

This does not mean that every anti-doping matter necessarily turns on a B sample. As we will see later, anti-doping violations can also be established through other reliable evidence in some circumstances.

But for the traditional positive-sample process, the A and B structure helps protect both evidence integrity and athlete rights.

Blood testing provides a different biological window

Blood testing is used because urine cannot answer every anti-doping question.

Venous blood can be useful for detecting certain prohibited substances or methods, examining circulating biomarkers, investigating blood manipulation, and supporting Athlete Biological Passport programs.

The sample is collected by appropriately qualified personnel. In Canada, venous blood draws are performed by certified blood collection officers.

Before collection, the athlete may be required to remain seated for a specified period. This is not arbitrary. Physical activity and posture can influence some blood measurements. Standardizing collection conditions helps make the result more scientifically meaningful.

Blood samples are then coded, sealed, documented, transported, and analyzed through processes designed to preserve sample integrity.

The important concept for the reader is that blood and urine provide different information.

Urine can be particularly useful for substances and metabolites excreted by the kidneys.

Blood can provide direct information about circulating molecules and biological markers.

For some anti-doping questions, collecting both may provide a stronger picture than either sample alone.

Dried blood spot testing adds another option

Dried blood spot testing, usually abbreviated DBS, provides another form of blood collection.

Instead of drawing a conventional tube of venous blood, a small amount of capillary blood is collected through a skin puncture and absorbed into a specialized collection medium.

Sport Integrity Canada began incorporating DBS into its testing program as an additional approved sample type. Canadian athletes under the CADP may be selected to provide urine, venous blood, or DBS samples.

DBS does not replace traditional urine or venous blood testing.

It supplements them.

That distinction is important because different sample types can be suited to different analytical targets. A smaller and more convenient blood collection method expands the tools available to the testing authority, but it does not make every other method unnecessary.

For the athlete, it also reinforces a broader lesson: there is no single universal anti-doping sample.

The testing authority chooses the sample type based on what it is trying to investigate.

The Athlete Biological Passport changes the question

Traditional anti-doping testing often asks whether a prohibited substance, metabolite, or marker can be identified in a sample.

The Athlete Biological Passport adds a different approach.

Instead of relying only on one isolated result, selected biological variables are measured over time to build a longitudinal profile of the individual athlete.

This is important because normal human biology varies from person to person. A value that looks unusual when compared with a broad population may be perfectly ordinary for one individual. Conversely, a value that still falls within a wide “normal range” may represent an unusual change for that particular athlete.

Longitudinal monitoring allows the athlete to be compared partly with their own previous pattern.

The haematological component of the passport examines blood-related variables associated with oxygen transport and potential blood manipulation. Anti-doping systems also use steroid-related longitudinal information, and the framework continues to evolve as biological monitoring becomes more sophisticated.

The passport does not mean that one strange blood result automatically establishes doping.

Training, illness, altitude exposure, hydration, travel, and other physiological factors can influence biological measurements.

Instead, atypical patterns can trigger scientific review, additional analysis, or more targeted testing.

This is one of the most important conceptual changes in modern anti-doping.

The system may not always need to begin by asking:

“Can we find the drug?”

It can sometimes begin by asking:

“Why has this athlete’s biological pattern changed?”

Polygraph testing is not the same thing

This distinction is especially important for readers involved in bodybuilding or other privately governed competitions.

A polygraph is not a laboratory drug test.

It does not analyze urine, blood, or tissue for a prohibited compound. Instead, it records physiological responses while a person answers questions.

Some natural bodybuilding organizations use polygraph examinations as part of their eligibility screening. Those organizations may combine polygraphs with laboratory testing, while others rely much more heavily on analytical testing.

For example, WNBF Canada currently describes a system involving pre-competition polygraph screening along with urinalysis for certain competitors. Other natural bodybuilding organizations use different systems and may place greater emphasis on laboratory testing.

This is why the phrase “drug tested federation” is incomplete.

The athlete needs to know what “tested” actually means.

Does the federation collect urine?

Does it collect blood?

Does it use a polygraph?

Who gets tested?

Is testing random?

Are winners tested?

Can testing occur outside competition?

What prohibited list does the federation use?

What period of prior use affects eligibility?

Those rules can differ significantly from one federation to another.

A polygraph should therefore be understood as an organizational screening or investigative tool rather than a substitute for chemical analysis.

Whereabouts allow some athletes to be found outside competition

Out-of-competition testing creates a practical problem.

If an anti-doping organization intends to test an athlete with no advance notice, it needs to know where that athlete can reasonably be located.

This is why whereabouts systems exist.

Athletes in designated registered testing pools can be required to submit information about their location and availability through systems such as ADAMS, the Anti-Doping Administration and Management System.

Not every athlete has this obligation.

That distinction matters because people sometimes hear about whereabouts rules and assume every amateur athlete must provide their daily schedule to an anti-doping organization.

They do not.

Whereabouts obligations apply to specific athlete groups identified under the applicable testing framework.

For athletes who are included, however, the requirements are significant because accurate location information allows unannounced testing to occur during training and outside competition.

Repeated failures relating to whereabouts can also have anti-doping consequences even when no prohibited substance has been found in a sample.

This is our first clear example of an important principle:

An anti-doping rule violation does not always require a positive drug test.

The laboratory receives evidence, not simply a bottle

Once a sample leaves the collection site, maintaining its integrity becomes critical.

The containers are sealed using tamper-evident systems and transported through a documented chain of custody.

The laboratory verifies that the sample identification and accompanying documentation are consistent and that the sample has arrived in appropriate condition.

In Canada, samples collected through Sport Integrity Canada’s program are analyzed through a WADA-accredited laboratory system. Sport Integrity Canada’s public guidance currently identifies the INRS Armand-Frappier Santé Biotechnologie Research Centre in Montréal as the laboratory receiving Canadian samples.

Accreditation matters because anti-doping laboratories must work within technical standards governing analytical methods, quality systems, reporting, sample security, and other aspects of testing.

The athlete should therefore think of the collection form, sample code, seal, transport record, and laboratory analysis as one continuous evidentiary chain.

A sophisticated analytical instrument cannot compensate for an unreliable sample.

Conversely, a perfectly collected sample is useful only if the laboratory method used to analyze it is scientifically valid.

Anti-doping depends on both.

Laboratory analysis is targeted and layered

Once a sample reaches the laboratory, the analysis depends on the sample type and the substances or methods being investigated.

There is no single instrument that simply flashes “clean” or “doped.”

Laboratories use different analytical techniques for different targets. These can include mass-spectrometry-based methods, hormone assays, isotope-ratio techniques, immunological methods, and biomarker analysis.

Some tests look for the prohibited substance itself.

Others look for metabolites.

Others examine ratios or biological markers.

Some substances require specialized analysis that may not be performed on every sample.

This is another reason a negative result should not be misunderstood as a universal statement that the athlete has never used any prohibited substance.

It means that the analyses performed on that sample did not produce a reportable finding under the applicable procedures.

Testing strategy matters.

Sample type matters.

Analytical target matters.

Timing matters.

And the technologies available at the time of testing matter.

Samples can be stored and tested again later

This is one of the parts of anti-doping that many athletes do not realize exists.

Certain samples may be placed into long-term storage and later subjected to further analysis. Under the WADA laboratory framework, appropriate urine and blood-derived samples can potentially be retained for up to ten years for this purpose.

Why would anyone re-test an old sample?

Because analytical science improves.

A substance that was difficult to detect when the sample was collected may later become easier to identify.

Scientists may discover a more useful metabolite.

A new analytical technique may improve sensitivity or specificity.

Investigators may obtain new information that makes a particular stored sample worth examining again.

The original competition may therefore be long over while the biological evidence still exists.

This dramatically changes the idea of what it means to “pass a test.”

An athlete may receive no adverse finding from the initial analysis, but that does not necessarily mean the sample has lost all future relevance.

The better way to think about it is:

The sample represents a biological record from a particular moment in time.

Our ability to read that record can improve.

What happens if the laboratory reports an adverse finding?

A laboratory finding does not usually move directly from an instrument to an automatic public suspension.

There is a results-management process.

The testing authority reviews the finding and considers matters required by the governing rules, which can include whether the athlete had an applicable medical exemption, whether the analytical and procedural requirements were satisfied, and whether further action is required.

The athlete is then notified in accordance with the applicable rules and has procedural rights.

Depending on the substance and circumstances, provisional suspension may also become relevant.

Where a B-sample analysis is available and requested or otherwise required, that process can form part of the case.

Eventually, the matter may be resolved through acceptance of consequences, a hearing, or another results-management mechanism provided by the governing rules.

The important principle is that laboratory science and disciplinary decision-making are related but distinct.

The laboratory answers an analytical question.

The results-management system determines what that analytical finding means under the rules.

A positive sample is not the only form of evidence

This may be one of the most important ideas in the entire section.

Anti-doping rules can recognize evidence beyond a traditional positive A sample.

Under the Canadian Anti-Doping Program, use or attempted use of a prohibited substance or method may, in appropriate circumstances, be established through other reliable means. These can include admissions, credible witness evidence, documentary evidence, analytical information, or conclusions drawn from longitudinal profiling such as the Athlete Biological Passport.

This is why anti-doping also includes intelligence and investigations.

Consider an obvious example.

If reliable evidence established that an athlete knowingly possessed and administered a prohibited substance, the absence of a positive urine test does not necessarily make that evidence disappear.

Likewise, conduct involving tampering, evading collection, trafficking, prohibited administration, complicity, or certain whereabouts failures can raise anti-doping issues that do not depend upon finding a prohibited molecule in a specimen.

This changes the popular understanding of drug testing.

Anti-doping is not merely a laboratory program.

It is a regulatory, scientific, and investigative system.

Refusing a test can itself create a problem

If an athlete is properly selected for testing under rules that apply to them, refusing to provide the required sample is not the same as providing a negative sample.

Athletes have procedural rights during doping control and can raise concerns, request information, request appropriate accommodations, or document objections.

But simply walking away from a valid testing request can create a separate anti-doping issue.

This is why athletes should understand their rights before they need them.

If something appears wrong during collection, the better approach is generally to raise the concern, document it through the available process, obtain appropriate advice, and follow the applicable rules rather than assuming refusal carries no consequences.

The athlete support team also matters

Modern anti-doping rules do not exist only for athletes.

Coaches, physicians, trainers, managers, and other athlete support personnel can also have responsibilities depending on their role and the governing framework.

This matters greatly with peptide-related substances because athletes may obtain information or products through people they trust.

A coach may suggest a recovery compound.

A clinic may recommend a treatment.

A trainer may provide something obtained through another athlete.

A medical professional may prescribe a medication without realizing that the patient competes under anti-doping rules.

From the athlete’s perspective, the recommendation may feel authoritative.

From the anti-doping system’s perspective, responsibility may extend to more than one person.

This is another reason athletes should not assume that “someone on my team gave it to me” resolves the issue.

Everyone involved needs to understand which rulebook they are answering.

How all of these pieces fit together

The anti-doping system works because no single element has to carry the entire burden.

The Prohibited List defines what substances and methods are restricted.

Athlete education helps competitors understand their responsibilities before problems occur.

Medication and exemption systems address legitimate medical needs.

Testing plans decide who should be tested and when.

Urine, blood, and dried blood spot samples provide different biological evidence.

The Athlete Biological Passport looks at patterns over time.

Laboratories use validated analytical methods to identify substances, metabolites, and markers.

Whereabouts programs make certain athletes accessible for no-notice testing.

Intelligence and investigations can identify issues that laboratory testing alone may miss.

Chain-of-custody procedures protect the reliability of the sample.

Results management protects due process after a potential violation is identified.

Long-term storage allows the science of tomorrow to revisit evidence collected today.

Taken together, this creates a system that is much broader than the familiar image of an athlete providing a urine sample after winning a race.

That broader understanding is especially important when discussing peptides. Some peptide-related substances may require specialized analytical methods. Some affect naturally occurring biological systems. Some may be identified through metabolites or biomarkers. Some may be relevant to longitudinal biological monitoring. Others may fall within anti-doping rules even when there is no laboratory finding at all.

The procedure therefore begins long before the athlete enters the doping-control station and can continue long after the initial sample has been analyzed.